Cargando…

Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis

Background: According to the 2023 guidelines for treating non-small-cell lung cancer (NSCLC), first-line treatment and recently developed agents for the treatment of epidermal growth factor (EGFR) mutation-positive locally advanced or metastatic NSCLC were compared in this meta-analysis. Treatment r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Wei, Miao, Julian, Wang, Ying, Xing, Wenzhong, Xu, Xiumei, Wu, Rui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358853/ https://www.ncbi.nlm.nih.gov/pubmed/37484016 http://dx.doi.org/10.3389/fphar.2023.1212313

Ejemplares similares

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
por: Shu, Yamin, et al.
Publicado: (2022)

EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
por: Nan, Xueli, et al.
Publicado: (2017)

Chinese Herbal Medicine Combined With First-Generation EGFR-TKIs in Treatment of Advanced Non-Small Cell Lung Cancer With EGFR Sensitizing Mutation: A Systematic Review and Meta-Analysis
por: Lu, Yan, et al.
Publicado: (2021)

Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective
por: Zhou, Kexun, et al.
Publicado: (2023)

Chinese Herbal Medicine (Yiqi-Yangyin-Jiedu Decoction) Combined With Osimertinib as First-Line Treatment in EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer (CATLA-2): A Study Protocol for a Double-Blind Randomized Controlled Trial
por: Yao, Jialin, et al.
Publicado: (2022)

Chinese Herbal Medicine Combined With EGFR-TKI in EGFR Mutation-Positive Advanced Pulmonary Adenocarcinoma (CATLA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Jiao, Lijing, et al.
Publicado: (2019)

Quantitative comparison of the efficacies and safety profiles of three first-line non-platinum chemotherapy regimens for advanced non-small cell lung cancer
por: Yang, Qian-Yu, et al.
Publicado: (2022)

Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
por: Liang, Sheng-Kai, et al.
Publicado: (2017)

Impact of Smoking on Response to the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis
por: Lin, Kehai, et al.
Publicado: (2022)

An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer
por: Qi, Yuexiao, et al.
Publicado: (2022)

Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
por: Lu, Shun, et al.
Publicado: (2021)

Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
por: Lee, Sung Yong, et al.
Publicado: (2021)

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
por: Chen, Po-Yen, et al.
Publicado: (2021)

Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer
por: Su, Po-Lan, et al.
Publicado: (2018)

Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non–small-cell Lung Cancer
por: Hao, Xuezhi, et al.
Publicado: (2021)

The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
por: Lu, Tingting, et al.
Publicado: (2023)

Prediction of EGFR Mutation Status in Non–Small Cell Lung Cancer Based on Ensemble Learning
por: Feng, Youdan, et al.
Publicado: (2022)

Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer
por: Hu, Haoyue, et al.
Publicado: (2023)

EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors
por: Xu, Haiyan, et al.
Publicado: (2022)

First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic
por: Lakkunarajah, Suganija, et al.
Publicado: (2023)

Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer
por: Yang, Szu-Chun, et al.
Publicado: (2018)

Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis
por: Hu, Di, et al.
Publicado: (2023)

Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer
por: Wang, Xiaohong, et al.
Publicado: (2021)

The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer
por: Su, Vincent Yi-Fong, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Sintilimab Combined with Chemotherapy Versus Chemotherapy Alone as the First-Line Treatment for Advanced Esophageal Cancer
por: Ye, Zhuo-Miao, et al.
Publicado: (2022)

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations
por: Haaland, Benjamin, et al.
Publicado: (2014)

First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis
por: Zhang, Hongwei, et al.
Publicado: (2019)

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
por: Chmielecki, Juliann, et al.
Publicado: (2023)

CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations
por: Kang, Liping, et al.
Publicado: (2023)

Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study
por: Zhou, Chun-Hua, et al.
Publicado: (2021)

Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review
por: Zhang, Xiao, et al.
Publicado: (2022)

Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non–Small Cell Lung Cancer
por: Liao, Dehua, et al.
Publicado: (2022)

Efficacy and safety of apatinib versus sorafenib/placebo in first-line treatment for intermediate and advanced primary liver cancer: A systematic review and meta-analysis
por: Peng, Dan, et al.
Publicado: (2023)

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting
por: Park, Keunchil, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With IIIB–IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health - Care System in China
por: Zhu, Chen, et al.
Publicado: (2021)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer
por: Wu, Meiyu, et al.
Publicado: (2022)

Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study
por: Liang, Sheng-Kai, et al.
Publicado: (2018)

Safety assessment of fluorescently labeled anti-EGFR Nanobodies in healthy dogs
por: do Valle, Nayra Cristina Herreira, et al.
Publicado: (2023)

Retrospective analysis of independent predictors of progression‐free survival in patients with EGFR mutation‐positive advanced non‐small cell lung cancer receiving first‐line osimertinib
por: Teranishi, Shuhei, et al.
Publicado: (2022)

Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer in China
por: Qiao, Liu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e9lllbimsdlmj50k3daaabhsng